基于表观遗传标志的液体活检在实体瘤诊疗中的研究与应用

国际肿瘤学杂志››2021,Vol. 48››Issue (6): 358-361.doi:10.3760/cma.j.cn371439-20200918-00068

基于表观遗传标志的液体活检在实体瘤诊疗中的研究与应用

庄伟涛^1,², 乔贵宾¹()

¹广东省医学科学院广东省人民医院胸外科,广州 510080
²汕头大学医学院 515041

收稿日期:2020-09-18修回日期:2020-09-26出版日期:2021-06-08发布日期:2021-06-24
通讯作者:乔贵宾 E-mail:guibinqiao@126.com
基金资助:
广东省科技创新战略专项(2020A1414070007)

Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors

Zhuang Weitao^1,², Qiao Guibin¹()

¹Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
²Shantou University Medical College, Shantou 515041, China

Received:2020-09-18Revised:2020-09-26Online:2021-06-08Published:2021-06-24
Contact:Qiao Guibin E-mail:guibinqiao@126.com
Supported by:
Special Project for Technical Innovation Strategy of Guangdong Province of China(2020A1414070007)

摘要/Abstract

摘要：

表观遗传学改变与肿瘤发生、发展和转归密切相关,在肿瘤精准及微创诊疗方面具有很好的应用潜力。DNA甲基化、羟甲基化与组蛋白修饰检测技术的进步,推动了基于表观遗传标志的液体活检研究的开展,在实体肿瘤的溯源定位、早期诊断、临床分期、疗效评价、复发监测及预后判断方面均取得了重要进展。

关键词:肿瘤,生物标记,表观基因组学,液体活检

Abstract:

Epigenetic changes are closely related to carcinogenesis, tumor progression and prognosis, which have a considerable potential in assisting the precision and minimally invasive management of cancers. The progress of detection techniques for DNA methylation, hydroxymethylation and histone modification has promoted the research works of liquid biopsy targeting epigenetic markers, and recently, important progress has been made in tumor location, early diagnosis, clinical staging, evaluation of treatment response, monitoring of recurrence and prognostic prediction of solid tumors.

Key words:Neoplasms,Biomarkers,tumor,Epigenomics,Liquid biopsy

庄伟涛, 乔贵宾. 基于表观遗传标志的液体活检在实体瘤诊疗中的研究与应用[J]. 国际肿瘤学杂志, 2021, 48(6): 358-361.

Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors[J]. Journal of International Oncology, 2021, 48(6): 358-361.

参考文献30

[1]	U.S. Food and Drug Administration. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test[EB/OL].[2020-08-11]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test.
[2]	Kang S, Li Q, Chen Q, et al. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA[J]. Genome Biol, 2017,18(1):53. DOI: 10.1186/s13059-017-1191-5. doi:10.1186/s13059-017-1191-5
[3]	Jensen SØ, Øgaard N, Ørntoft MW, et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study[J]. Clin Epigenetics, 2019,11(1):158. DOI: 10.1186/s13148-019-0757-3. doi:10.1186/s13148-019-0757-3
[4]	Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test[J]. Nat Commun, 2020,11(1):3475. DOI: 10.1038/s41467-020-17316-z. doi:10.1038/s41467-020-17316-z
[5]	Widschwendter M, Zikan M, Wahl B, et al. The potential of circula-ting tumor DNA methylation analysis for the early detection and management of ovarian cancer[J]. Genome Med, 2017,9(1):116. DOI: 10.1186/s13073-017-0500-7. doi:10.1186/s13073-017-0500-7pmid:29268796
[6]	Sheaffer KL, Elliott EN, Kaestner KH. DNA hypomethylation contributes to genomic instability and intestinal cancer initiation[J]. Cancer Prev Res (Phila), 2016,9(7):534-546. DOI: 10.1158/1940-6207.CAPR-15-0349. doi:10.1158/1940-6207.CAPR-15-0349pmid:26883721
[7]	Margalit S, Avraham S, Shahal T, et al. 5-Hydroxymethylcytosine as a clinical biomarker: fluorescence-based assay for high-throughput epigenetic quantification in human tissues[J]. Int J Cancer, 2020,146(1):115-122. DOI: 10.1002/ijc.32519. doi:10.1002/ijc.32519pmid:31211411
[8]	Pfeifer GP, Szabó PE. Gene body profiles of 5-hydroxymethylcytosine: potential origin, function and use as a cancer biomarker[J]. Epigenomics, 2018,10(8):1029-1032. DOI: 10.2217/epi-2018-0066. doi:10.2217/epi-2018-0066pmid:30052061
[9]	Zeng C, Stroup EK, Zhang Z, et al. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy[J]. Cancer Commun (Lond), 2019,39(1):12. DOI: 10.1186/s40880-019-0356-x.
[10]	Li D, Zeng Z. Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis[J]. Biosci Rep, 2019, 39(8): BSR20191815. DOI: 10.1042/BSR20191815.
[11]	Chrun ES, Modolo F, Daniel FI. Histone modifications: a review about the presence of this epigenetic phenomenon in carcinogenesis[J]. Pathol Res Pract, 2017,213(11):1329-1339. DOI: 10.1016/j.prp.2017.06.013. doi:10.1016/j.prp.2017.06.013
[12]	Li YH, Li YX, Li M, et al. The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer[J]. Life Sci, 2020,256:117936. DOI: 10.1016/j.lfs.2020.117936. doi:10.1016/j.lfs.2020.117936
[13]	Chae YK, Davis AA, Jain S, et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer[J]. Mol Cancer Ther, 2017,16(7):1412-1420. DOI: 10.1158/1535-7163.MCT-17-0061. doi:10.1158/1535-7163.MCT-17-0061
[14]	Guo Q, Wang J, Xiao J, et al. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing[J]. Mol Cancer, 2018,17(1):131. DOI: 10.1186/s12943-018-0875-0. doi:10.1186/s12943-018-0875-0
[15]	Huang J, Wang L. Cell-free DNA methylation profiling analysis-technologies and bioinformatics[J]. Cancers (Basel), 2019,11(11):1741. DOI: 10.3390/cancers11111741. doi:10.3390/cancers11111741
[16]	Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J]. Nature, 2018,563(7732):579-583. DOI: 10.1038/s41586-018-0703-0. doi:10.1038/s41586-018-0703-0pmid:30429608
[17]	Shen SY, Burgener JM, Bratman SV, et al. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA[J]. Nat Protoc, 2019,14(10):2749-2780. DOI: 10.1038/s41596-019-0202-2. doi:10.1038/s41596-019-0202-2pmid:31471598
[18]	Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine[J]. Nat Biotechnol, 2011,29(1):68-72. DOI: 10.1038/nbt.1732. doi:10.1038/nbt.1732
[19]	Song CX, Yin S, Ma L, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages[J]. Cell Res, 2017,27(10):1231-1242. DOI: 10.1038/cr.2017.106. doi:10.1038/cr.2017.106
[20]	Zeng H, He B, Xia B, et al. Bisulfite-free, nanoscale analysis of 5-Hydroxymethylcytosine at single base resolution[J]. J Am Chem Soc, 2018,140(41):13190-13194. DOI: 10.1021/jacs.8b08297. doi:10.1021/jacs.8b08297
[21]	Yuan F, Yu Y, Zhou YL, et al. 5hmC-MIQuant: ultrasensitive quantitative detection of 5-hydroxymethylcytosine in low-input cell-free DNA samples[J]. Anal Chem, 2020,92(1):1605-1610. DOI: 10.1021/acs.analchem.9b04920. doi:10.1021/acs.analchem.9b04920
[22]	Reddy D, Khade B, Pandya R, et al. A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumours[J]. Clin Epigenetics, 2017,9:30. DOI: 10.1186/s13148-017-0330-x. doi:10.1186/s13148-017-0330-x
[23]	Hlady RA, Zhao X, Pan X, et al. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA[J]. Theranostics, 2019,9(24):7239-7250. DOI: 10.7150/thno.35573. doi:10.7150/thno.35573pmid:31695765
[24]	Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes[J]. Nat Med, 2020,26(7):1044-1047. DOI: 10.1038/s41591-020-0932-2. doi:10.1038/s41591-020-0932-2
[25]	Nuzzo PV, Berchuck JE, Korthauer K, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes[J]. Nat Med, 2020,26(7):1041-1043. DOI: 10.1038/s41591-020-0933-1. doi:10.1038/s41591-020-0933-1
[26]	Ko JMY, Ng HY, Lam KO, et al. Liquid biopsy serial monitoring of treatment responses and relapse in advanced esophageal squamous cell carcinoma[J]. Cancers (Basel), 2020,12(6):1352. DOI: 10.3390/cancers12061352. doi:10.3390/cancers12061352
[27]	Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA[J]. Proc Natl Acad Sci U S A, 2016,113(13):E1826-E1834. DOI: 10.1073/pnas.1519286113. doi:10.1073/pnas.1519286113
[28]	Barault L, Amatu A, Siravegna G, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer[J]. Gut, 2018,67(11):1995-2005. DOI: 10.1136/gutjnl-2016-313372. doi:10.1136/gutjnl-2016-313372
[29]	Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis[J]. Lancet Respir Med, 2018,6(10):771-781. DOI: 10.1016/S2213-2600(18)30284-4. doi:S2213-2600(18)30284-4pmid:30100403
[30]	Jensen LH, Olesen R, Petersen LN, et al. NPY gene methylation as a universal, longitudinal plasma marker for evaluating the clinical benefit from last-line treatment with regorafenib in metastatic colorectal cancer[J]. Cancers (Basel), 2019,11(11):1649. DOI: 10.3390/cancers11111649. doi:10.3390/cancers11111649